NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000000835

Registered date:15/10/2007

Assesment for Responses to Cilnidipine in Diabetic Nephropathy with Hypertension

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedDiabetic nephropathy with hypertension
Date of first enrollment2007/08/01
Target sample size120
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)L-CCB/Cilnidipine group: Switch to 6 month-treatment with cilnidipine after L-CCB administration for at least 6 months Cilnidipine/L-CCB group: Switch to 6 month-treatment with L-CCB after cilnidipine administration for at least 6 months

Outcome(s)

Primary Outcome1. Change in urinary excretion of albumin or protein 2. Change in serum creatinin level or GFR 3. Blood pressure lowering effects. Achievement of target blood pressure, <130/80 mmHg (<125/75 mmHg in case of more than 1g/day of urinary protein excretion)
Secondary OutcomeChange in plasma glucose, HbA1C, insulin, total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, urinary NAG excretion, or blood AGE levels, urinary BMG.

Key inclusion & exclusion criteria

Age minimum18years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteria(1) Contraindication to Ca-channel blocker (2) The patient who is judged to be inappropriate for this study by the doctor in charge.

Related Information

Contact

public contact
Name Shinya Fukumoto
Address 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan Japan
Telephone 06-6645-3806
E-mail sfukumoto@med.osaka-cu.ac.jp
Affiliation Osaka City University Graduate School of Medicine Department of Metabolism, Endocrinology and Molecular Medicine
scientific contact
Name Shinya Fukumoto
Address 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan Japan
Telephone 06-6645-3806
E-mail
Affiliation Osaka City University Graduate School of Medicine Department of Metabolism, Endocrinology and Molecular Medicine